CTRI/2024/08/072197
Not yet recruiting
Phase 2
An Interventional Trial to Evaluate the Impact of GLUBLOC™ on HbA1c levels, Glycemic Variability and Time in Range in Type 2 diabetic individuals. - NI
INU Energy Pvt Ltd0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- INU Energy Pvt Ltd
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age: 25 \- 65 years old male and non\-pregnant females
- •Diagnosis of Type 2 Diabetes Mellitus for at least 6 months; treated with stable dose of oral anti\-diabetic drugs (drugs permitted: metformin, sulfonylureas) for at least 3 months before screening.
- •Participants with HbA1c between 7 to 11 percent
- •Participant willing to provide informed consent and willing to comply with study procedures
Exclusion Criteria
- •Type 1 Diabetes Mellitus participants.
- •Type 2 Diabetes Mellitus participants on insulin, Thiazolidinediones, GLP\-1 agonists, DPP\-IV inhibitors, AGI’s and/or SGLT2 inhibitors.
- •Allergy to one or more components of the investigational product or history of food allergies
- •Participant receiving any diabetes specific nutritional food supplement apart from multivitamin/ mineral supplements (Ca/Vit D supplements and B complex syrups) within 15 days prior to study start.
- •Participant taking any herbal/ayurvedic/ alternative medicine preparations that could profoundly affect blood glucose.
- •Females who are nursing / pregnant / are of child \- bearing potential and not practicing an acceptable method of birth control / or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
- •Participant has evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease, which in the opinion of the investigator, can adversely affect study outcome/s.
- •Participant with active infection in past 30 days.
- •Participant has a history of any episode(s) of severe hypoglycemia (requiring third party assistance), disabling diabetic neuropathy including autonomic neuropathy, gastroparesis or lower limb ulceration or amputation or evidence or history of diabetic complications with significant end organ damage.
- •Participants on any pharmacological therapy of modern or alternative medicine for management of obesity in past 6 months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Counselling by nurse will improve medical adherence, patient satisfaction, sinonasal quality and visual quality of life in post operative patients of pituitary tumors.Health Condition 1: E229- Hyperfunction of pituitary gland,unspecifiedCTRI/2019/06/019505Postgraduate Institute of Medical Education and Research Chandigarh60
Not yet recruiting
Phase 3
Karshyahara lauha a potent herbomineral powder to increase Hb or HemoglobiCTRI/2024/08/071906Dr Sunil Sukumar Shirahatti
Not yet recruiting
Phase 3
A Clinical trial to evaluate the effect of Ayurvedic drugs and Yoga therapy on Male InfertilityCTRI/2021/03/031646BH
Not yet recruiting
Phase 2
Effect of Inspiratory Muscle Strength Training (IMST) on Blood PressureAmong Older AdultsHealth Condition 1: I10- Essential (primary) hypertensionCTRI/2024/08/071780Fogarty International Center - National Institutes of Health (NIH)
Recruiting
Phase 1
VECTORS – A study to evaluate transmural healing as a treatment target in Crohn’s diseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]CTIS2023-509096-16-00Alimentiv Inc.266